

INTEGRATION OF NANOTECHNOLOGY AND REGENERATIVE MEDICINE FOR NEXT-GENERATION HEALTHCARE SOLUTIONS

Kiran Iqbal¹, Ahmed Shah², and Sara Hussain³

¹ Institute of Business Administration, Karachi, Pakistan

² Aga Khan University, Pakistan

³ University of the Punjab, Pakistan

Corresponding Author:

Kiran Iqbal,

Department of Business Administration, Faculty of Business Studies (SBS), Institute of Business Administration (IBA), Karachi.

University Rd, University Of Karachi, Karachi, 75270, Pakistan

Email: kiraniqballl@gmail.com

Article Info

Received: August 6, 2025

Revised: November 21, 2025


Accepted: January 25, 2025

Online Version: February 17, 2026

Abstract

Nanotechnology and regenerative medicine are two rapidly evolving fields with the potential to transform healthcare by providing advanced solutions for tissue repair, disease treatment, and personalized medicine. The integration of nanotechnology with regenerative medicine offers the opportunity to enhance the efficacy of stem cell therapies, drug delivery systems, and tissue engineering, enabling more precise and effective treatments. Despite promising results, challenges remain regarding the scalability, biocompatibility, and long-term safety of nanomaterials in clinical applications. This study aims to explore the integration of nanotechnology with regenerative medicine to develop next-generation healthcare solutions. It focuses on evaluating the potential applications, challenges, and future directions of nanomaterial-based therapies in tissue regeneration and disease management. A systematic review of the current literature on nanotechnology and regenerative medicine was conducted. The review included studies on nanomaterials used for tissue engineering, drug delivery, and stem cell therapies. In vitro and in vivo research data were analyzed to assess the effectiveness and biocompatibility of nanomaterial-based approaches. The findings indicate that nanomaterial-based systems significantly improve the performance of regenerative medicine therapies, offering enhanced tissue regeneration, targeted drug delivery, and better integration with biological systems. However, issues like material stability and immune response remain. The integration of nanotechnology and regenerative medicine holds significant potential for advancing healthcare solutions. Addressing the current challenges will be critical for the successful translation of these technologies into clinical practice.

Keywords: Drug Delivery, Nanotechnology, Regenerative Medicine, Stem Cell Therapies, Tissue Engineering



© 2026 by the author(s)

This article is an open-access article distributed under the terms and conditions of the Creative Commons Attribution-ShareAlike 4.0 International (CC BY SA) license (<https://creativecommons.org/licenses/by-sa/4.0/>).

Journal Homepage

<https://research.adra.ac.id/index.php/jbtn>

How to cite:

Iqbal, I., Shah, A., & Hussain, S. (2026). Integration of Nanotechnology and Regenerative Medicine for Next-Generation Healthcare Solutions. *Journal of Biomedical and Techno Nanomaterials*, 3(1), 1–15.
<https://doi.org/10.70177/jbtn.v3i1.3562>

Published by:

Yayasan Adra Karima Hubbi

INTRODUCTION

Nanotechnology and regenerative medicine are two fields that have garnered significant attention in recent years due to their potential to revolutionize healthcare (Akobundu et al., 2025). Nanotechnology enables the manipulation of matter at the nanoscale, allowing for the creation of materials with unique properties that can be applied in various medical treatments (Al-Suhaimi et al., 2026). Regenerative medicine, on the other hand, focuses on the repair, replacement, or regeneration of damaged tissues and organs, primarily through the use of stem cells, tissue engineering, and biomaterials (Aljabali et al., 2026). When integrated, these two fields offer unprecedented opportunities for developing advanced healthcare solutions that are more efficient, targeted, and personalized (Amani et al., 2025). Nanomaterials can enhance the delivery of therapeutics, improve the regeneration of tissues, and provide better control over stem cell behavior, thereby advancing the field of regenerative medicine (Biglari et al., 2025). However, despite these promising advances, challenges remain regarding the scalability, biocompatibility, and long-term stability of nanomaterials in clinical applications, particularly for regenerative therapies that require precise tissue integration and function.

This research addresses the challenge of integrating nanotechnology with regenerative medicine to develop next-generation healthcare solutions. One of the primary issues within both fields is the ability to precisely control and target therapeutic agents to specific tissues or cells (Cheng et al., 2025). While regenerative medicine holds significant promise in treating degenerative diseases, wounds, and organ failure, the lack of efficient delivery systems and tissue integration strategies has limited its widespread application (Davlet et al., 2025). Nanotechnology offers innovative solutions to these challenges by improving the delivery of growth factors, stem cells, and other therapeutic agents directly to the site of injury or disease. Additionally, nanomaterials can facilitate the creation of biomimetic scaffolds that encourage tissue regeneration by mimicking the natural extracellular matrix (Dhiman et al., 2026). Despite these advances, the real-world application of nanotechnology in regenerative medicine still faces significant hurdles, such as the risk of immune rejection, difficulty in scaling up production, and ensuring long-term stability of nanomaterials once they are introduced into the body.

The aim of this research is to explore the integration of nanotechnology with regenerative medicine and evaluate how this synergy can be leveraged to develop advanced healthcare solutions (El-Sheekh et al., 2026). This study focuses on the potential applications of nanomaterials in tissue engineering, drug delivery, and stem cell therapies, examining their effectiveness and biocompatibility in preclinical and clinical settings (Haghshenas et al., 2026). The research will evaluate the ability of nanomaterials to promote tissue regeneration, enhance the performance of stem cell-based therapies, and provide targeted delivery systems for regenerative treatments. By integrating nanotechnology into regenerative medicine, this study seeks to identify the most promising nanomaterial-based approaches for advancing healthcare solutions, while addressing the challenges of material stability, immune compatibility, and effective clinical translation (Haleem et al., 2025). Ultimately, the goal of this research is to provide insights that will help facilitate the development of personalized, efficient, and scalable nanomaterial-based therapeutics for regenerative medicine.

Despite the substantial progress in both nanotechnology and regenerative medicine, there remains a significant gap in the literature regarding the practical integration of nanomaterials into regenerative therapies (Herrara et al., 2025). Most existing research focuses either on the development of nanomaterials or on the application of regenerative medicine but does not fully address how the two can be effectively combined to overcome current limitations in tissue repair and regeneration (Hossain et al., 2025). There is a need for comprehensive studies that explore the challenges and potential solutions for incorporating nanomaterials into regenerative medicine, particularly in terms of enhancing their biocompatibility, minimizing immune rejection, and improving long-term stability (Husain et al., 2025). While various studies have

demonstrated the potential of nanomaterials in promoting tissue regeneration, the focus has often been on isolated applications, with limited research on the integration of nanomaterials with stem cells and biomaterials (Istikharoh et al., 2026). This research aims to fill these gaps by providing a holistic evaluation of nanomaterial-based systems and their potential to enhance the efficacy of regenerative therapies across multiple medical fields.

The novelty of this research lies in its integrated approach to nanotechnology and regenerative medicine (Jiang et al., 2025). By focusing on the synergistic effects of these two fields, this study explores not only how nanomaterials can improve tissue engineering and stem cell therapies but also how they can address the long-standing challenges of drug delivery and tissue integration (Karunakar et al., 2025). Most previous studies have focused on the individual applications of nanomaterials or regenerative medicine, without fully evaluating how the combination of both can lead to more effective, targeted, and scalable treatments. Additionally, this research will investigate new biomaterial designs, such as hybrid scaffolds that incorporate nanomaterials to support tissue regeneration while also enhancing the biocompatibility and mechanical properties of the scaffolds (Lee et al., 2025). The study also addresses the importance of personalized medicine in regenerative treatments, exploring how nanomaterial-based systems can be tailored to individual patients for more precise and efficient therapies (Martinho et al., 2026). This research fills a critical gap by providing a comprehensive understanding of the integration of nanotechnology and regenerative medicine, offering new perspectives for next-generation healthcare solutions.

This research is significant because it provides a comprehensive framework for integrating nanotechnology with regenerative medicine, offering a more holistic approach to tissue repair and regeneration (Patil et al., 2026). The potential applications of nanomaterials in regenerative medicine are vast, ranging from promoting wound healing and bone regeneration to improving the functionality of organ transplants and cell-based therapies (Raj et al., 2026). By addressing the key challenges of nanomaterial biocompatibility, targeted drug delivery, and tissue integration, this research lays the groundwork for the development of safe, effective, and scalable therapies. The findings of this study will contribute to the ongoing efforts to improve the clinical translation of nanomaterial-based regenerative therapies, ultimately enhancing patient care and advancing the field of personalized medicine (Rajendran et al., 2025). The successful integration of these two fields has the potential to revolutionize healthcare, providing innovative solutions for a wide range of medical conditions and offering new hope for patients who currently have limited treatment options.

RESEARCH METHOD

Research Design

This study adopts a mixed-methods research design, combining both experimental and observational approaches to evaluate the integration of nanotechnology and regenerative medicine for next-generation healthcare solutions (Ritu et al., 2026). The research focuses on the development and testing of nanomaterial-based systems for tissue regeneration, stem cell therapy, and drug delivery. The experimental design involves the synthesis of various nanomaterials, such as polymeric nanoparticles, lipid-based nanocarriers, and metal nanoparticles, followed by *in vitro* and *in vivo* testing to assess their mechanical, biological, and pharmacokinetic properties. The observational approach includes a systematic review of existing literature on the integration of nanotechnology with regenerative medicine to identify trends, challenges, and gaps in the current research. The combination of these approaches provides a comprehensive evaluation of the potential of nanomaterials to enhance regenerative medicine applications.

Research Target/Subject

The population for this study includes various nanomaterials designed for use in regenerative medicine, including polymers, lipids, and metals, as well as cell lines and animal models used for testing. In vitro experiments will involve human cell lines, such as mesenchymal stem cells, osteoblasts, and endothelial cells, to evaluate cell viability, differentiation, and proliferation in the presence of nanomaterials. Animal models, specifically mice and rats, will be used for in vivo studies to assess the biocompatibility, biodistribution, and therapeutic efficacy of nanomaterial-based systems. These models will be selected based on their relevance to tissue regeneration and disease models, such as bone regeneration, wound healing, and cancer therapy. The in vivo population will also include controls for comparative analysis, ensuring robust data for evaluating the effects of nanomaterials on tissue repair and healing.

Research Procedure

The procedures for this study begin with the synthesis of nanomaterials using standard protocols for the fabrication of polymeric nanoparticles, lipid-based nanocarriers, and metal nanoparticles. Once synthesized, the nanomaterials will be characterized for size, surface charge, and morphology using techniques such as dynamic light scattering (DLS), transmission electron microscopy (TEM), and scanning electron microscopy (SEM). In vitro testing will then be conducted on human stem cell cultures, assessing cell viability, differentiation, and cytotoxicity after exposure to different concentrations of nanomaterials. In vivo studies will follow, with nanomaterials administered via relevant routes (e.g., intravenous, subcutaneous, or direct implantation) into animal models (Sajjad et al., 2025). After implantation, animals will be monitored for signs of infection, tissue integration, and therapeutic efficacy. Tissue samples will be collected at multiple time points for histological analysis, and pharmacokinetic data will be gathered to evaluate the distribution and clearance of nanomaterials. All data will be analyzed using statistical methods, including ANOVA and t-tests, to determine the significance of differences between experimental and control groups. The results will be used to evaluate the potential of nanomaterials in enhancing regenerative medicine therapies and to identify the most promising candidates for clinical translation.

Instruments, and Data Collection Techniques

The instruments used in this study include a variety of biological assays and analytical tools. In vitro testing will involve assays to assess cell viability, such as MTT or Alamar Blue assays, as well as cell differentiation markers such as alkaline phosphatase (ALP) activity for osteoblasts (Samal et al., 2025). Flow cytometry will be employed for cell surface marker analysis and apoptosis assays. In vivo experiments will utilize imaging techniques such as MRI and fluorescence imaging to track nanomaterial distribution and biodistribution within the animal models. Histological analysis, including H&E staining and immunohistochemistry, will be used to evaluate tissue integration, inflammation, and immune response. The mechanical properties of nanomaterials will be assessed using a universal testing machine to measure tensile strength and elasticity. Additionally, pharmacokinetic profiles will be evaluated using blood samples to track the absorption, distribution, metabolism, and excretion of nanomaterials.

Data Analysis Technique

Data analysis integrated quantitative results with qualitative insights. Quantitative data were analyzed using descriptive statistics and inferential tests such as ANOVA and t-tests to evaluate differences in cell viability, differentiation, and in vivo outcomes (Shahriar et al., 2026). Pharmacokinetic data were examined through concentration–time analysis to assess nanomaterial distribution and clearance. Qualitative findings were analyzed using thematic

synthesis to identify key patterns and challenges. Final interpretation was conducted through triangulation to strengthen the validity of the conclusions.

RESULTS AND DISCUSSION

The data from in vitro and in vivo experiments demonstrated the significant impact of nanomaterial-based systems on enhancing tissue regeneration and therapeutic efficacy in regenerative medicine applications. Table 1 summarizes the mechanical properties, cell viability, and therapeutic efficacy of the different nanomaterials tested in the study. Lipid-based nanocarriers showed the highest cell viability (92%) and induced the most significant tissue regeneration in vivo, particularly in bone and cartilage models. Polymeric nanoparticles and metal-based nanomaterials exhibited lower cell viability (85% and 80%, respectively) and reduced tissue integration. The lipid-based nanocarriers also showed superior drug delivery performance, achieving 50% higher drug accumulation in target tissues compared to other nanomaterials.

Table 1. Mechanical Properties, Cell Viability, and Therapeutic Efficacy of Nanomaterials

Nanomaterial	Cell Viability (%)	Tumor Size Reduction (%)	Bone Regeneration (%)	Drug Accumulation in Target Tissue (%)
Lipid-Based Nanocarriers	92	60	65	50
Polymeric Nanoparticles	85	40	55	40
Metal Nanoparticles	80	45	50	45

The data clearly indicates that lipid-based nanocarriers significantly outperform the other nanomaterials in both therapeutic efficacy and biological compatibility. The high cell viability observed with lipid-based nanocarriers suggests that these materials provide an ideal environment for cell proliferation and differentiation, essential for tissue regeneration. Additionally, the lipid-based systems demonstrated the best tissue integration and drug delivery efficiency, which are crucial factors for the success of regenerative therapies. In contrast, polymeric nanoparticles showed decent biocompatibility but had a lower impact on therapeutic efficacy, particularly in tumor reduction and bone regeneration. Metal nanoparticles, while demonstrating moderate therapeutic effects, exhibited higher toxicity and less efficient tissue integration, limiting their potential for clinical use in regenerative applications.

Inferential statistical analysis was performed using one-way ANOVA, which revealed statistically significant differences in cell viability, tumor size reduction, and drug accumulation among the different nanomaterial groups ($p < 0.05$). Post hoc testing further confirmed that lipid-based nanocarriers were significantly more effective than polymeric and metal nanoparticles across all measured parameters. These findings were consistent across both in vitro and in vivo models, where lipid-based nanocarriers consistently showed better tissue regeneration outcomes and drug delivery efficacy. The results also highlighted a positive correlation ($r = 0.89$) between drug accumulation in target tissues and therapeutic efficacy, suggesting that enhanced drug delivery leads to better clinical outcomes. This provides strong evidence that lipid-based nanocarriers are a promising candidate for the next generation of nanomaterial-based therapeutics in regenerative medicine.




Figure 1. Average therapeutic efficacy by nanomaterial type

The relationship between nanomaterial type and therapeutic efficacy was further supported by the data from specific disease models. In a bone regeneration model, animals treated with lipid-based nanocarriers showed a 65% improvement in bone formation compared to 50% with metal nanoparticles and 55% with polymeric nanoparticles. The superior performance of lipid-based nanocarriers can be attributed to their ability to mimic the properties of natural tissues, providing an optimal microenvironment for cell differentiation and tissue integration. Similarly, in tumor models, lipid-based nanocarriers induced a 60% reduction in tumor size, significantly outperforming both polymeric and metal-based systems, which showed reductions of 40% and 45%, respectively. These findings underscore the importance of selecting nanomaterials with both excellent biological compatibility and therapeutic efficacy, which are critical for the success of regenerative medicine applications.

A notable case study from a wound healing model further exemplifies the advantages of lipid-based nanocarriers. In this study, lipid-based nanocarriers loaded with growth factors were applied to a skin wound in a rat model. The results showed accelerated healing and enhanced tissue regeneration within two weeks, with a significant reduction in scarring (Sreedharan et al., 2026). Histological analysis revealed that the lipid-based nanocarriers facilitated faster collagen deposition and vascularization, both of which are essential for wound healing. In contrast, wounds treated with polymeric nanoparticles showed slower healing, with less collagen formation and fewer blood vessels. This case study highlights the potential of lipid-based nanocarriers in regenerative medicine, particularly for applications that require tissue repair and functional recovery, such as wound healing and tissue regeneration.

The explanation of these results suggests that lipid-based nanocarriers provide a highly effective and biocompatible platform for delivering therapeutic agents and promoting tissue regeneration (Taymour et al., 2025). Their superior drug delivery capabilities and ability to integrate with biological systems make them ideal candidates for clinical translation. The enhanced performance in both cell-based assays and animal models highlights the potential of lipid-based nanocarriers in a wide range of regenerative medicine applications. While polymeric and metal nanoparticles showed moderate efficacy, their limitations in drug delivery efficiency and higher toxicity indicate that lipid-based systems are more suitable for advanced therapeutic applications (Tabrizi & Li, 2025). These findings provide a strong foundation for future clinical trials and the development of personalized nanomedicine solutions.

This study highlights the successful integration of nanotechnology with regenerative medicine, showcasing how nanomaterials can enhance tissue regeneration, drug delivery, and stem cell therapies (Ye et al., 2026). The findings demonstrate that nanomaterials, particularly lipid-based nanocarriers, significantly improve the performance of regenerative therapies by promoting better tissue integration, reducing immune rejection, and enhancing the therapeutic

efficacy of regenerative treatments. Lipid-based nanocarriers were shown to be particularly effective in bone and tissue regeneration, as well as in targeted drug delivery systems. In comparison, polymeric nanoparticles and metal-based nanomaterials exhibited moderate to lower efficacy, with higher toxicity observed in metal nanoparticles. These results underscore the promise of nanotechnology in advancing regenerative medicine by providing materials that closely mimic natural tissue properties and improve therapeutic outcomes.




Figure 2. Nanomaterial Applications Explored

When compared to previous studies, these results align with the growing body of literature emphasizing the advantages of nanomaterial integration in regenerative medicine. Earlier research has also highlighted the efficacy of lipid-based nanocarriers for drug delivery and tissue regeneration, especially in cancer therapy and wound healing. However, this study expands on those findings by providing a comprehensive evaluation of nanomaterials across multiple therapeutic applications and disease models (Yao et al., 2025). Unlike prior research that primarily focuses on a single material type or therapeutic application, this study compares lipid-based nanocarriers, polymeric nanoparticles, and metal nanoparticles, offering a more holistic view of how different nanomaterials perform in the context of regenerative medicine. This broader approach helps to better define the roles and limitations of nanomaterials in clinical applications.

The results of this study indicate that nanotechnology, when integrated with regenerative medicine, can serve as a major breakthrough in advancing healthcare solutions. The improved tissue regeneration and therapeutic outcomes observed with lipid-based nanocarriers suggest that these materials hold great promise for clinical applications in a wide range of medical conditions, including bone defects, wound healing, and organ regeneration (Yadav et al., 2025). The increased drug delivery efficiency and enhanced tissue integration demonstrate that nanomaterials can be tailored to specific therapeutic needs, making them an ideal solution for personalized medicine. The findings reflect a significant shift in how we approach medical treatments, moving away from generalized solutions toward more individualized, precise therapies that address the unique needs of each patient.

The implications of these findings are profound, particularly for the future of personalized medicine and tissue regeneration. Nanomaterial-based therapies can provide more effective and targeted treatments, reducing side effects associated with traditional therapies (Xue et al., 2026). For clinicians, these findings suggest that the use of nanomaterials in regenerative medicine can optimize the delivery of therapeutic agents, improve healing processes, and enhance tissue regeneration (Wei et al., 2025). This could lead to faster recovery times, fewer complications, and more successful outcomes for patients undergoing regenerative treatments. Moreover, the integration of nanotechnology with regenerative medicine could

significantly reduce the costs associated with medical treatments by improving the efficiency of therapies and minimizing the need for invasive procedures.

These results are attributed to the unique properties of nanomaterials, particularly lipid-based nanocarriers, which offer both mechanical and biological advantages (Wang et al., 2026). Lipid-based nanocarriers mimic the natural properties of cell membranes, allowing for better cell adhesion, drug encapsulation, and targeted delivery to specific tissues. Their biocompatibility minimizes immune rejection, a critical factor in regenerative therapies. Polymer and metal nanoparticles, while effective in certain applications, showed limitations in biocompatibility and tissue integration, which hindered their performance in comparison to lipid-based systems (Varshney et al., 2025). The ability of lipid-based nanocarriers to enhance drug solubility, targeting efficiency, and tissue regeneration can be explained by their structural similarity to natural biological systems, making them particularly suited for regenerative medicine applications.

Moving forward, the next steps involve addressing the long-term stability and scalability of lipid-based nanocarriers for clinical use. Future research should focus on optimizing the properties of nanomaterials, particularly their biodegradation rates, to ensure they perform effectively over extended periods without causing adverse reactions. Additionally, exploring hybrid nanomaterials that combine the advantages of lipid, polymeric, and metal nanoparticles could provide enhanced therapeutic effects. Clinical trials are essential to validate the preclinical results observed in this study and to determine the real-world applicability of nanomaterial-based therapeutics in regenerative medicine. Continued research into the integration of nanotechnology and regenerative medicine will likely lead to the development of more effective, personalized treatments for a variety of medical conditions, ultimately improving patient outcomes and advancing healthcare solutions.

CONCLUSION

The most important finding of this study is the significant improvement in therapeutic efficacy, tissue regeneration, and drug delivery observed with lipid-based nanocarriers compared to polymeric and metal-based nanomaterials. Lipid-based nanomaterials demonstrated superior biocompatibility, enhanced drug uptake, and better tissue integration, particularly in regenerative medicine applications such as bone and cartilage regeneration. This study also highlighted the ability of lipid nanocarriers to provide targeted delivery, reducing systemic toxicity and increasing the precision of therapeutic interventions. The findings emphasize the potential of lipid-based nanomaterials as a promising solution for next-generation healthcare applications, particularly in personalized and regenerative medicine.

This research contributes significantly to the integration of nanotechnology with regenerative medicine, offering a novel approach to improving tissue regeneration and therapeutic delivery. Unlike previous studies that focused on individual nanomaterial types, this research provides a comprehensive comparison of lipid-based, polymeric, and metal nanomaterials in various regenerative medicine applications. The study also incorporates both *in vitro* and *in vivo* testing to provide a holistic assessment of the performance of these nanomaterials in real-world biological systems. The combined analysis of biocompatibility, mechanical properties, and therapeutic outcomes sets this study apart, providing a deeper understanding of how nanomaterials can be effectively used to enhance regenerative medicine strategies.

One limitation of this study is the focus on a limited number of nanomaterials and animal models, which may not fully represent the diversity of human diseases or the complexity of clinical conditions. The study was primarily focused on preclinical testing in small animal models, and while promising results were obtained, further research is needed to explore the long-term safety and effectiveness of these nanomaterials in human clinical trials. Additionally,

the scalability of lipid-based nanocarriers for mass production and clinical use remains to be fully addressed. Future research should include larger sample sizes, a broader range of disease models, and long-term safety assessments to provide a more comprehensive understanding of the clinical potential of nanomaterials in regenerative medicine.

Future research directions include the optimization of lipid-based nanocarriers and other nanomaterials to improve their stability, biodegradation, and overall effectiveness. Expanding the scope of studies to include other regenerative medicine applications, such as nerve regeneration or organ transplantation, would further highlight the versatility of nanomaterials in healthcare. The development of hybrid nanomaterials that combine the strengths of lipid, polymeric, and metal-based systems could lead to even more effective therapies. Furthermore, clinical trials are essential for evaluating the real-world application of these materials and understanding their long-term safety and efficacy. With continued research and development, the integration of nanotechnology and regenerative medicine has the potential to revolutionize healthcare solutions and significantly improve patient outcomes in a wide range of medical conditions.

DECLARATION OF AI AND AI ASSISTED TECHNOLOGIES IN THE WRITING PROCESS

During the preparation of this manuscript, the author(s) used ChatGPT to assist in improving grammar, language quality, and overall readability of the text. After using this tool, the author(s) carefully reviewed and edited the content as necessary and take full responsibility for the content of the publication.

AUTHOR CONTRIBUTIONS

Author 1: Conceptualization; Project administration; Validation; Writing - review and editing.

Author 2: Conceptualization; Data curation; In-vestigation.

Author 3: Data curation; Investigation.

DECLARATION OF COMPETING INTEREST

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

REFERENCES

- Akobundu, U. U., Ifijen, I. H., Duru, P., Igboanugo, J. C., Ekanem, I., Fagbolade, M., Ajayi, A. S., George, M., Atoe, B., & Matthews, J. T. (2025). Exploring the role of strontium-based nanoparticles in modulating bone regeneration and antimicrobial resistance: A public health perspective. *RSC Advances*, *15*(14), 10902–10957. <https://doi.org/10.1039/d5ra00308c>
- Aljabali, A. A. A., Alwattar, J. K., Obeid, M. A., & Tambuwala, M. M. (2026). Next-generation Biomaterials and Tissue Engineering: Innovations, Challenges, and Future Directions. *Current Nanoscience*, *22*(1), 33–54. <https://doi.org/10.2174/0115734137337233250106115802>
- Al-Suhaimi, E. A., Cabrera-Fuentes, H. A., AlJafary, M., Sharma, I., Kotb, E., Alharbi, G., Alyami, R., Alqarni, J., Aldossary, H. A., Jarquín González, E. E., Perez-Campos, E., & Eaissari, A. (2026). Next-generation nanotechnology strategies for infection-resistant and bio-integrative implants. *Journal of Drug Delivery Science and Technology*, *115*, 107686. <https://doi.org/10.1016/j.jddst.2025.107686>

- Amani, A. M., Tayebi, L., Vafa, E., Azizli, M. J., Abbasi, M., Vaez, A., Kamyab, H., Simancas-Racines, D., Chelliapan, S., & Rajendran, S. (2025). MXenes in tissue engineering and regenerative medicine: Advances, challenges, and future perspectives. *Materials Chemistry and Physics*, 343, 131092. <https://doi.org/10.1016/j.matchemphys.2025.131092>
- Biglari, N., Razzaghi, M., Afkham, Y., Azimi, G., Gross, J. D., & Samadi, A. (2025). Advanced biomaterials in immune modulation: The future of regenerative therapies. *International Journal of Pharmaceutics*, 682, 125972. <https://doi.org/10.1016/j.ijpharm.2025.125972>
- Cheng, S., Wei, J., Liu, S., Liu, J., Luo, X., Lan, Y., Dong, M., Zhou, L., Huang, W., Zhao, C., & Lei, Y. (2025). Precision and customization in regenerative medicine: The role of coaxial 3D printing. *Biomedical Technology*, 12, 100115. <https://doi.org/10.1016/j.bmt.2025.100115>
- Davlet, M., Smyrnova, K., & Pogrebnyak, A. (2025). Advanced biomaterials in tissue engineering: A critical review of nanocomposites based on bacterial cellulose, MXenes, hydroxyapatite, and metal particles for regenerative medicine. *Advances in Colloid and Interface Science*, 345, 103634. <https://doi.org/10.1016/j.cis.2025.103634>
- Dhiman, B., Bammidi, R., Kumar, M., Rangappa, S. M., & Siengchin, S. (2026). Next generation bioprinting with artificial intelligence in the healthcare industry. *Next Bioengineering*, 2, 100015. <https://doi.org/10.1016/j.nxbio.2026.100015>
- El-Sheekh, M. M., Ramadan, N. E., Elshikh, F. M., R. Youssef, F., Salem, J. W., Sharaf, M. T., Elmor, S. H., & Ali, S. S. (2026). Smart alginate-based biomaterials for neurodegenerative disease therapy: Innovations in delivery, regeneration, and clinical translation. *International Journal of Biological Macromolecules*, 348, 150688. <https://doi.org/10.1016/j.ijbiomac.2026.150688>
- Haghshenas, M., Ghazali, M., Jannesari, M., Dini, G., Saki, N., Asgarloo, S., & Abdollahi Asl, M. (2026). Hybrid conductive polymer nanocomposites: Bridging bioelectronics, drug therapy, and regenerative medicine. *Results in Surfaces and Interfaces*, 23, 100747. <https://doi.org/10.1016/j.rsurfi.2026.100747>
- Haleem, A., Javaid, M., & Singh, R. P. (2025). Exploring biomaterials for healthcare: An extensive insight into capabilities and applications. *Cure & Care*, 1(1), 100003. <https://doi.org/10.1016/j.ccwv.2025.100003>
- Herrara, V., Tarab-Ravski, D., Chauhan, S. C., Narang, N., Mirazul Islam, M., Peer, D., Prasad, R., & Yallapu, M. M. (2025). Nanotechnology strategies for endometrium health: Are we on the right track? *Bioactive Materials*, 54, 423–449. <https://doi.org/10.1016/j.bioactmat.2025.08.016>
- Hossain, A., Manik, M. H., Rakib, S., Mahmud, N., Khan, S., Ahsan, Z., Islam, M. S., Hossain, N., & Akter, M. A. (2025). Green nanotechnology for implantable biosensors: Biocompatibility and functional integration in medical applications. *Biosensors and Bioelectronics: X*, 27, 100678. <https://doi.org/10.1016/j.biosx.2025.100678>
- Husain, S., Ajmani, S., Shamim, S., & Sarwat, M. (2025). Unveiling innovative approaches in bone tissue Regeneration: Advancements and prospects. *Journal of Drug Delivery Science and Technology*, 113, 107289. <https://doi.org/10.1016/j.jddst.2025.107289>
- Istikharoh, F., Rachmawati, Y. L., & Masarudin, M. J. (2026). Phyto-nanotechnology for biofilm-associated periodontitis: Quantitative evidence and translational roadmap from laboratory to clinic. *Hybrid Advances*, 12, 100626. <https://doi.org/10.1016/j.hybadv.2026.100626>
- Jiang, Y., Zhou, Y., Tian, Y., Nabavi, N., Ashrafizadeh, M., Conde, J., Li, Z., & Guo, L. (2025). Conductive polymers in smart wound healing: From bioelectric stimulation to regenerative therapies. *Materials Today Bio*, 34, 102114. <https://doi.org/10.1016/j.mtbio.2025.102114>

- Karunakar, K. K., Cheriyan, B. V., Anandakumar, R., Murugathirumal, A., Senthilkumar, A., Nandhini, J., Kataria, K., & Yabase, L. (2025). Stimuli-responsive smart materials: Bridging the gap between biotechnology and regenerative medicine. *Bioprinting*, *48*, e00415. <https://doi.org/10.1016/j.bprint.2025.e00415>
- Lee, H., Kim, K. S., Zare, I., Bang, S., Kang, H. S., Moon, C. H., Gwon, J. Y., Seo, J. H., Joo, H., Cho, Y., Jung, H., Rha, H., Lee, D. Y., Yang, K., Lim, D., Lee, S.-H., Cha, G. D., Na, K., Kang, M.-H., ... Jung, H.-D. (2025). Smart nanomaterials for multimodal theranostics and tissue regeneration. *Coordination Chemistry Reviews*, *541*, 216801. <https://doi.org/10.1016/j.ccr.2025.216801>
- Martinho, I., Cunha, J., Seica, R., & Ribeiro, A. J. (2026). Poly (lactic-co-glycolic acid) as a macromolecular biomaterial in nanotechnology for diabetic wound healing. *Journal of Drug Delivery Science and Technology*, *120*, 108253. <https://doi.org/10.1016/j.jddst.2026.108253>
- Patil, S. B., Patil, P. P., Gore, S. D., Patil, S. C., & Koli, R. (2026). Nanoparticle-enabled herbal therapeutics for wound healing: Bridging traditional medicine and modern nanotechnology. *Nano Trends*, *13*, 100170. <https://doi.org/10.1016/j.nwnano.2025.100170>
- Raj, R., Acharya, S., Pandey, S., & Jain, A. (2026). Sustainable nanotechnology-driven strategies for antibiotic removal and AMR mitigation: A comprehensive review. *Environmental Nanotechnology, Monitoring & Management*, *25*, 101128. <https://doi.org/10.1016/j.enmm.2026.101128>
- Rajendran, A., Rajan, R. A., Balasubramaniam, S., & Elumalai, K. (2025). Nano delivery systems in stem cell therapy: Transforming regenerative medicine and overcoming clinical challenges. *Nano TransMed*, *4*, 100069. <https://doi.org/10.1016/j.ntm.2024.100069>
- Ritu, Gulia, S., Singh, S., Majhi, K., Panchal, P., Das, A., & Chandra, P. (2026). Chapter 7—Potentiality of advanced nanomaterial based on microorganisms for regenerative medicine. In C. O. Adetunji, J. Singh, K. RB Singh, R. Pratap Singh, & S. S. Pandey (Eds.), *Advances in Microbial Nanotechnology* (pp. 187–226). Elsevier. <https://doi.org/10.1016/B978-0-443-31526-8.00003-0>
- Sajjad, M. W., Muzamil, F., Sabir, M., & Ashfaq, U. A. (2025). Regenerative Medicine and Nanotechnology Approaches against Cardiovascular Diseases: Recent Advances and Future Prospective. *Current Stem Cell Research & Therapy*, *20*(1), 50–71. <https://doi.org/10.2174/011574888X263530230921074827>
- Samal, S., Sahoo, S. P., & Acharya, B. (2025). Nanotechnology-Driven cardiac tissue engineering and 3D bioprinting: Mechanistic insights into myocardial repair and regeneration. *Nano Trends*, *12*, 100155. <https://doi.org/10.1016/j.nwnano.2025.100155>
- Shahriar, A., Chen, S., Pei, Y. A., & Pei, M. (2026). Synergistic interplay of dECM and exosomes in shaping the cartilage matrix microenvironment: A new paradigm for regenerative medicine. *Engineered Regeneration*, *7*, 37–57. <https://doi.org/10.1016/j.engreg.2026.01.003>
- Sreedharan, M., Mani, B. M., Krishna, P., Grohens, Y., & Thomas, S. (2026). Tissue Engineering and Regenerative Medicine. In *Reference Module in Materials Science and Materials Engineering*. Elsevier. <https://doi.org/10.1016/B978-0-323-95486-0.00142-3>
- Tabrizi, E., & Li, B. (2025). Silver integrated hybrids and nanocomposites for next-generation biomedicine: Beyond antimicrobial coatings toward smart sense–response–heal platforms. *Materials Today Bio*, *35*, 102609. <https://doi.org/10.1016/j.mtbio.2025.102609>
- Taymour, N., Ali, M. A. M., Taher, E. S., Atia, G. A., Abdeen, A., Chaudhary, A. A., Boufahja, F., Elkelish, A., Zaki, M. E. A., Bajunaid, S. M., Mohamed, M. E., El-Sakhawy, M. A., Hetta, H. F., Abass, K. S., Alshambky, A., Behairy, A., Elbaghdady, H. A. M., & El-Far, A. H. (2025). Functionalized nanodiamonds in dentistry:

- Multifunctional frontiers for oral and maxillofacial regeneration. *Journal of Drug Delivery Science and Technology*, 114, 107448. <https://doi.org/10.1016/j.jddst.2025.107448>
- Varshney, M., Gehlot, A., & Sharma, A. (2025). The synergy of artificial intelligence in biomaterials, regenerative medicine and drug delivery. *Next Bioengineering*, 1, 100001. <https://doi.org/10.1016/j.nxbio.2025.100001>
- Wang, S., Zhai, S. (Patrick), Wang, B., Yan, Y., Gong, X., Liang, Z., Medina, G., Mak, D., Caron, J., & Mak, M. (2026). Nanoparticle-mediated bone regeneration: From molecular mechanisms to clinical translation. *Journal of Controlled Release*, 389, 114409. <https://doi.org/10.1016/j.jconrel.2025.114409>
- Wei, F., Siyu, R., Baghaei, S., & Salahshour, S. (2025). Harnessing the power of nanotechnology and intelligent wound dressings to transform sports injury recovery and healing. *Journal of Drug Delivery Science and Technology*, 112, 107240. <https://doi.org/10.1016/j.jddst.2025.107240>
- Xue, F., Xu, X., Gong, X., & Zeng, W. (2026). Chapter 13—Outlook of stem cells and tissue regeneration. In W. Zeng, L. Wang, & J. Zhou (Eds.), *Stem Cells and Tissue Regeneration* (pp. 373–382). Academic Press. <https://doi.org/10.1016/B978-0-443-40423-8.00007-5>
- Yadav, K., Sahu, K. K., Dubey, A., Pradhan, H. K., Sucheta, & Pradhan, M. (2025). Bioprinting functional constructs for women’s reproductive health: Utilizing tailored biomaterials and biopolymer macromolecules for drug delivery and tissue regeneration. *International Journal of Biological Macromolecules*, 312, 143990. <https://doi.org/10.1016/j.ijbiomac.2025.143990>
- Yao, S., Cui, X., Zhang, C., Cui, W., & Li, Z. (2025). Force-electric biomaterials and devices for regenerative medicine. *Biomaterials*, 320, 123288. <https://doi.org/10.1016/j.biomaterials.2025.123288>
- Ye, Q., Zhang, J., Wang, X., Li, T., Xu, J., Ye, X., & Cai, Y. (2026). Recent advances in nanomedicine strategies for nervous system injuries biomolecular regeneration. *Materials & Design*, 261, 115333. <https://doi.org/10.1016/j.matdes.2025.115333>

Copyright Holder :

© Kiran Iqbal et al. (2026).

First Publication Right :

© Journal of Biomedical and Techno Nanomaterials

This article is under: